Featured Research

from universities, journals, and other organizations

Two Drugs Work Better Together Than Either Alone Against Kidney Cancer

Date:
July 31, 2007
Source:
Duke University Medical Center
Summary:
A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study.

A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.

"We found that by combining a drug that enlists the immune system's help in combating cancer with one that cuts off a tumor's blood supply, we could substantially increase patients' response rates to treatment," said Jared Gollob, M.D., an oncologist at Duke and lead investigator on the study.

Interferon alpha, an immunotherapy agent that boosts the body's own abilities to fight off infections and tumors, has been used for several decades to treat advanced renal cell carcinoma. But kidney tumors only respond to interferon alpha about 5 percent to 10 percent of the time, Gollob said.

The second drug, sorafenib, which is sold as Nexavar, is a member of a promising class of drugs known as anti-angiogenics, which work by choking a tumor's blood supply and thereby restricting its growth. But sorafenib causes substantial tumor shrinkage in only 5 percent to 10 percent of kidney cancer patients, Gollob said. Even in these patients, it can slow the progression of the disease but does not offer a cure.

"Most tumors that respond to either therapy alone begin growing again after about five or six months," Gollob said. "By using interferon alpha and sorafenib in combination, we not only increased the response rate, but found we could double the amount of time that these patients could survive without their tumors growing."

When used in combination, the drugs led to significant tumor shrinkage in 33 percent of the 40 patients who participated in the study, and two of the patients had complete responses, meaning their tumors were destroyed, Gollob said. Study participants all had renal cell carcinoma that had already spread to other organs, known as stage IV disease.

The researchers gave the study patients sorafenib in a pill form twice daily and interferon alpha via injection three times a week for eight-week cycles. If the patient's tumor had not grown or had shrunk after eight weeks, the cycle would be repeated after a two-week break, until the tumors disappeared or until the cancer got worse. The researchers monitored the patients' progress using computerized-tomography (CT) scans that show the size of the tumors.

Based on the success of this study, researchers will soon begin a multi-site confirmatory trial that will take this study one step further by seeking to determine whether patients show additional progress when they take increasing doses of sorafenib alone after achieving maximum tumor shrinkage with the dual therapy, Gollob said.

Kidney cancer afflicts about 50,000 people per year in the United States according to the American Cancer Society. Most patients are over 45, and men are affected more than women. Kidney cancer generally does not cause symptoms until it has reached an advanced stage, when it can lead to blood in the urine, pain in the abdomen, fever, sweats, fatigue and anemia, Gollob said. When it has advanced to stage IV, the cancer has spread to organs such as the lungs, liver and bone.

Most people currently facing a diagnosis of stage IV kidney cancer survive anywhere from six months to two years, and only about ten percent are alive five years after diagnosis, Gollob said..

One of the biggest challenges facing doctors who treat kidney cancer is its resistance to chemotherapy, radiation and other common cancer-fighting tools, Gollob said. So doctors have relied on drugs such as interferon alpha and sorafenib, which benefit more patients, he said.

"This is a deadly cancer that has been hard to treat, and the results of our study suggest that we may be able to further improve the efficacy of exciting new drugs like sorafenib," he said.

The researchers published their findings in the August 1, 2007 issue of the Journal of Clinical Oncology. The study was funded by the National Cancer Institute

Other researchers involved in this study were Tina Richmond, Christine Marino, Elizabeth Miller, Lin Gu and Bercedis Peterson of Duke; Kimryn Rathmell, Gayle Grigson and Catherine Watkins of the University of North Carolina Lineberger Comprehensive Cancer Center; and John Wright of the National Cancer Institute.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Two Drugs Work Better Together Than Either Alone Against Kidney Cancer." ScienceDaily. ScienceDaily, 31 July 2007. <www.sciencedaily.com/releases/2007/07/070730181511.htm>.
Duke University Medical Center. (2007, July 31). Two Drugs Work Better Together Than Either Alone Against Kidney Cancer. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2007/07/070730181511.htm
Duke University Medical Center. "Two Drugs Work Better Together Than Either Alone Against Kidney Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/07/070730181511.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins